Stifel lowers Adient stock price target to $24 from $29, maintains Buy rating

Published 06/11/2025, 17:14
Stifel lowers Adient stock price target to $24 from $29, maintains Buy rating

Investing.com - Stifel lowered its price target on Adient (NYSE:ADNT) to $24.00 from $29.00 on Thursday while maintaining a Buy rating on the automotive seating supplier. The new target aligns closely with InvestingPro’s Fair Value assessment, suggesting the stock may be undervalued at its current price of $19.09.

The price target reduction follows Adient’s fiscal fourth-quarter 2025 results, which showed revenue exceeding consensus estimates while EBITDA came in slightly below analyst expectations. The company reported $14.54 billion in revenue and $754 million in EBITDA for the last twelve months.

Adient also provided guidance for fiscal year 2026, with projected revenue aligning with consensus forecasts but EBITDA falling "materially below" market expectations. Analysts are projecting earnings per share of $2.05 for fiscal 2026 despite recent challenges.

Stifel noted that Adient’s management appears to have incorporated a "relatively negative scenario" regarding production disruptions stemming from recent customer supply chain issues in its fiscal 2026 outlook.

The firm suggested that Adient’s guidance could potentially be revised upward if production recovers throughout calendar year 2026.

In other recent news, Adient PLC reported its Q4 2025 earnings, showcasing a revenue of $3.7 billion, which marks a 4% increase compared to the previous year. The company also achieved an adjusted EBITDA of $226 million. Notably, Adient exceeded earnings per share (EPS) expectations by reporting $0.52 against the forecasted $0.50. These results highlight the company’s ability to surpass analyst projections in terms of EPS. Despite these positive financial metrics, the stock experienced a decline in pre-market trading. Analysts and investors are closely monitoring these developments as they assess the company’s future performance. The earnings report provides critical insights into Adient’s recent financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.